根据2025年ESMO数据,在手术前和手术后新的药物组合将无资格接受切片化疗的膀胱癌患者的癌症累进或死亡率削减60%。 A new drug combo before and after surgery cut cancer progression or death by 60% in bladder cancer patients ineligible for cisplatin chemo, per 2025 ESMO data.

手术前和手术后使用Padcev和Keyturda的新型复方疗法,大大改善了无法接受切片化疗的肌肉侵入性膀胱癌患者的治疗结果,将癌症发病或死亡风险降低60%,与单是外科手术相比,死亡风险降低50%。 A new combination therapy using Padcev and Keytruda before and after surgery significantly improved outcomes for patients with muscle-invasive bladder cancer who cannot receive cisplatin-based chemotherapy, reducing the risk of cancer progression or death by 60% and lowering the risk of death by 50% compared to surgery alone. 3阶段EV-303/KEYNOTE-905试验在2025年ESMO大会上提出,试验显示,治疗无事件和总体存活情况有所改善,74.7%的病人在两年内没有疾病,而39.4%的病人只接受外科手术。 Presented at the 2025 ESMO Congress, the Phase 3 EV-303/KEYNOTE-905 trial showed the treatment improved event-free and overall survival, with 74.7% of patients remaining free of disease events at two years versus 39.4% in the surgery-only group. 57.1%的患者在综合体中获得了完全的病理反应,而外科组中这一比例为8.6%。 A pathologic complete response was achieved in 57.1% of patients on the combination, compared to 8.6% in the surgery group. 调查结果表明,治疗可能成为一种新的护理标准,提供改善长期生存的希望,并减少对清除膀胱的需求。 The findings suggest the treatment may become a new standard of care, offering hope for improved long-term survival and reduced need for bladder removal.